Assessment of Immune Correlates of Protection via Controlled Vaccine Efficacy and Controlled Risk
通过受控疫苗效力与受控风险评估免疫保护相关指标AI 解读 ↓
← 返回论文列表与筛选
阅读说明
本页整理公开书目信息，不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成，未完成全文核验，可能有误；具体假设、证明与结论请核对原文。摘要保留来源文本，未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要；缺少可靠材料时保留待补状态。
本页为预印本版本；arXiv 收录、作者填写的期刊信息以及作者既有发表经历，都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对，只展示已核实例，档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录，不合计多个记录；关联记录可能包含正式发表版本，不等于此版本单独引用。缺失不视为零，引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配，同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列，再参考通用方法与发表日期。
分类依据与纠错
AI 根据所提供的论文材料归类：摘要明确区分风险相关性与因果保护作用，并定义标志物干预下的受控风险和疫苗效力，直接属于因果推断。
反馈分类问题
正在核对关联版本…
代码、数据与补充材料
正在核对对应版本的资源…
通过受控疫苗效力与受控风险评估免疫保护相关指标
- 研究问题
- 如何区分免疫标志物与感染风险的相关性和因果保护作用，并用固定标志物水平下的受控疫苗效力评价其价值？
- 方法与思路
- 作者定义受控风险与疫苗效力曲线，通过可处理标志物缺失的回归调整已测混杂，并对未测混杂进行敏感性分析。
- 材料陈述的贡献
- 摘要提出因果保护相关指标的曲线评估框架，并称两项登革热三期试验的分析支持中和抗体滴度作为此类指标的价值。
- 阅读关注点
- 应核对设定标志物水平的干预含义、受控风险识别与缺失处理条件，以及未测混杂敏感性参数和保守修正方式。
- 阅读边界
- 这是arXiv预印本，同行评审与期刊接收未核实；摘要虽给出试验估计与区间，仍不足以判断识别假设及替代终点资格。
原文摘要
Immune correlates of protection (CoPs) are immunologic biomarkers accepted as a surrogate for an infectious disease clinical endpoint and thus can be used for traditional or provisional vaccine approval. To study CoPs in randomized, placebo-controlled trials, correlates of risk (CoRs) are first assessed in vaccine recipients. This analysis does not assess causation, as a CoR may fail to be a CoP. We propose a causal CoP analysis that estimates the controlled vaccine efficacy curve across biomarker levels $s$, $CVE(s)$, equal to one minus the ratio of the controlled-risk curve $r_C(s)$ at $s$ and placebo risk, where $r_C(s)$ is causal risk if all participants are assigned vaccine and the biomarker is set to $s$. The criterion for a useful CoP is wide variability of $CVE(s)$ in $s$. Moreover, estimation of $r_C(s)$ is of interest in itself, especially in studies without a placebo arm. For estimation of $r_C(s)$, measured confounders can be adjusted for by any regression method that accommodates missing biomarkers, to which we add sensitivity analysis to quantify robustness of CoP evidence to unmeasured confounding. Application to two harmonized phase 3 trials supports that 50% neutralizing antibody titer has value as a controlled vaccine efficacy CoP for virologically confirmed dengue (VCD): in CYD14 the point estimate (95% confidence interval) for $CVE(s)$ accounting for measured confounders and building in conservative margin for unmeasured confounding increases from 29.6% (95% CI 3.5 to 45.9) at titer 1:36 to 78.5% (95% CI 67.9 to 86.8) at titer 1:1200; these estimates are 17.4% (95% CI -14.4 to 36.5) and 84.5% (95% CI 79.6 to 89.1) for CYD15.